Summary
- Current Price
- As of today, GMAB price is $30.16, up +1.93% in the most recent trading session on
- Current Price All-Time High
- GMAB price is currently -70.77% below its historical high of $103.19 set on
- Market Cap
- GMAB current market cap is $19B, up +40.66% over the past 365 days
- PE Ratio
- GMAB current PE ratio is 12.81
- Revenue
- GMAB current annual revenue is $3.12B, up +30.60% year-over-year
- Next Earnings
- The next earnings release for GMAB is on
Profile
| Metric | Value |
|---|---|
| Full Name | Genmab A/S |
| Ticker | NASDAQ: GMAB |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Denmark |
| IPO | |
| Indexes | Not included |
| Website | genmab.com |
| Employees | 2,638 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $30.16 | |
| Price, 1D Change | +1.93% | |
| Market Cap | $19B | |
| - | ||
| PE Ratio | 12.81 | |
| Beta | 0.61 | |
| Revenue | $3B | |
| Revenue, 1Y Change | +30.60% | |
| EPS | $1.76 | |
| EPS, 1Y Change | +83.72% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 5:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | GMXAY | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $1.76 | |
| EPS Estimate | $1.91 | |
| EPS Est. Change | +8.63% | |
| Revenue | $3.12B | |
| Revenue Estimate | $23.75B | |
| Revenue Est. Change | +660.79% | |
| Current Price | $30.16 | |
| Price Target | - | $38.50 |
| Price Tgt. Change | - | +27.65% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $12.27 | $0.96 | -92.19% | |
| $1.25 | $1.76 | +40.74% | |
| $1.91 | N/A | +8.62% | |
| $1.49 | N/A | -15.47% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.38B | $2.39B | +0.35% | |
| $21.29B | $3.12B | -85.34% | |
| $23.75B | N/A | +660.79% | |
| $27.49B | N/A | +780.63% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +44.17% | |
| Price, 3Y | -23.20% | |
| Market Cap, 1Y | +40.66% | |
| Market Cap, 3Y | -27.19% | |
| Revenue, 1Y | +30.60% | |
| Revenue, 3Y | +131.57% | |
| EPS, 1Y | +83.72% | |
| EPS, 3Y | +143.16% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $30.16 | |
| SMA 200 | $27.03 | |
| SMA 200 vs Price | -10.37% | |
| SMA 50 | $32.38 | |
| SMA 50 vs Price | +7.36% | |
| Beta | 0.61 | |
| ATR | $0.95 | |
| 14-Day RSI | 34.92 | |
| 10-Day Volatility | 24.66% | |
| 1-Year Volatility | 36.49% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $3.12B | |
| EPS | $1.76 | |
| Gross Profit | $2.92B | |
| Gross Margin | 93.51% | |
| Operating Profit | $1.02B | |
| Operating Margin | 32.53% | |
| Net Income | $1.14B | |
| Net Margin | 36.44% | |
| EBITDA | $1.08B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.03 | |
| 5.25 | ||
| 5.24 | ||
| - | ||
| 7 | ||
| 11.19 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 12.81 | |
| 5.21 | ||
| 3.25 | ||
| 11.10 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $5.10B | |
| $2.93B | ||
| $6.36B | ||
| $3.87B | ||
| $1.27B | ||
| $737.06M | ||
| Total Debt | $142.88M | |
| $12.77M | ||
| $483.50M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $1.98B | ||
| $1.90B | ||
| $202.74M | ||
| $0.00 | ||
| $59.89M | ||
| $0.00 | ||
| $191.43M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $1.13B | ||
| -$1.44B | ||
| -$568.34M | ||
| Capex | $44.09M | |
| $1.08B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Truist Securities | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Guggenheim | → | |
| Guggenheim | → | |
| HC Wainwright & Co. | → | |
| Truist Securities | → |
Analyst sentiment
Institutional ownership
Screeners with GMAB
FAQ
What is the ticker symbol for Genmab A/S?
The ticker symbol for Genmab A/S is NASDAQ:GMAB
Does Genmab A/S pay dividends?
No, Genmab A/S does not pay dividends
What sector is Genmab A/S in?
Genmab A/S is in the Healthcare sector
What industry is Genmab A/S in?
Genmab A/S is in the Biotechnology industry
What country is Genmab A/S based in?
Genmab A/S is headquartered in Denmark
When did Genmab A/S go public?
Genmab A/S initial public offering (IPO) was on June 1, 2009
Is Genmab A/S in the S&P 500?
No, Genmab A/S is not included in the S&P 500 index
Is Genmab A/S in the NASDAQ 100?
No, Genmab A/S is not included in the NASDAQ 100 index
Is Genmab A/S in the Dow Jones?
No, Genmab A/S is not included in the Dow Jones index
When was Genmab A/S last earnings report?
Genmab A/S's most recent earnings report was on November 6, 2025
When does Genmab A/S report earnings?
The next expected earnings date for Genmab A/S is February 17, 2026
Data Sources & References
- GMAB Official Website www.genmab.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1434265/000143426525000092/0001434265-25-000092-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1434265/000155837025000846/0001558370-25-000846-index.htm
- GMAB Profile on Yahoo Finance finance.yahoo.com/quote/GMAB
- GMAB Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/gmab